Karyopharm Therapeutics Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$48.6M
Doctors Paid
7,608
Transactions
31,668
2024 Total
$5.6M
Payment Breakdown by Category
Research$41.4M (85.1%)
Consulting$1.1M (2.2%)
Food & Beverage$602,075 (1.2%)
Travel$570,945 (1.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $41.4M | 6,942 | 85.1% |
| Honoraria | $4.5M | 1,540 | 9.2% |
| Consulting Fee | $1.1M | 464 | 2.2% |
| Food and Beverage | $602,075 | 20,925 | 1.2% |
| Travel and Lodging | $570,945 | 1,058 | 1.2% |
| Space rental or facility fees (teaching hospital only) | $182,200 | 56 | 0.4% |
| Charitable Contribution | $150,000 | 1 | 0.3% |
| Grant | $70,000 | 3 | 0.1% |
| Education | $61,781 | 659 | 0.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $53,953 | 13 | 0.1% |
| Compensation for serving as faculty or as a speaker for a medical education program | $14,175 | 7 | 0.0% |
Payments by Type
Research
$41.4M
6,942 transactions
General
$7.2M
24,726 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Phase 1/2 Study of Selinexor in Combination with SOC Therapy for Newly Diagnosed or Recurrent Glioblastoma | $5.0M | 0 | 1,778 |
| XPORT-COV-1001 | $3.5M | 0 | 261 |
| A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | $2.3M | 0 | 666 |
| A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer | $2.1M | 1 | 697 |
| Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination with Multiple Standard Chemotherapy Agents in Patients with Advanced Malignancies | $1.9M | 0 | 6 |
| A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma | $1.8M | 0 | 335 |
| A phase 2 open-label multicenter study to evaluate the safety and efficacy of selinexor + pembrolizumab in recurrent advanced melanoma | $1.8M | 0 | 324 |
| KCP-330-020 | $1.7M | 0 | 286 |
| A Phase 2-3 Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) versus Placebo in Patients with Advanced Unresectable Dedifferentiated Liposarcoma (DDLS) | $1.7M | 0 | 306 |
| A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma | $1.6M | 0 | 257 |
| A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications | $1.6M | 1 | 199 |
| A PHASE 2 OPEN-LABEL MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SELINEXOR WITH OR WITHOUT PEMBROLIZUMAB VERSUS STANDARD OF CARE IN PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER WITH RAS MUTATIONS | $1.0M | 0 | 51 |
| A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) | $1.0M | 0 | 253 |
| A Phase 2B study of selinexor (KPT-330), in combination with carfilzomib, daratumumab or pomalidomide in patients with multiple myeloma relapsing on current therapy | $983,226 | 0 | 6 |
| KCP-330-017A | $831,280 | 0 | 118 |
| A Phase 1/2 Study of Selinexor in Combination With Standard of Care (SoC) Therapy for Newly Diagnosed or Recurrent Glioblastoma | $828,550 | 0 | 82 |
| A Phase 2/3, Multicenter, Randomized, Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | $784,107 | 0 | 219 |
| KCP-330-024 | $625,379 | 0 | 189 |
| A phase 2, randomized, open-label, multicenter study of Selinexor or Physicians choice in patients with myelofibrosis | $589,757 | 0 | 82 |
| 3300012 | $585,610 | 0 | 1 |
| Phase 1/2 Trial of Selinexor in COmbination with Carfilzomib, Pomalidomide and DexamethasonE (SCOPE) for Patients with Proteasome-inhibitor and Immunomodulatory Drug Refractory Multiple Myeloma | $562,224 | 0 | 5 |
| KCP-330-012 | $539,046 | 0 | 52 |
| A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients with Severe COVID-19 iNFECTION | $530,833 | 0 | 126 |
| A Multicenter, Phase 1/2 Study of Selinexor in Combination with Backbone Treatments or Novel Therapies in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma | $484,371 | 0 | 24 |
| A PHASE 1 OPEN-LABEL STUDY OF KPT-9274 IN PATIENTS WITH RELAPSED AND REFRACTORY ACUTE MYELOID LEUKEMIA | $400,000 | 0 | 2 |
| Part I: A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Dexamethasone in Patients with Multiple Myeloma Exposed to Bortezomib, Carfilzomib, Lenalidomide and Pomalidomide and Refractory to an IMiD and a Proteasome Inhibitor.Part II: A Phase 2b, Open Label, Single-Arm Study of Selinexor (KPT-330), Plus Low Dose Dexamethasone (Sd) in Patients with Multiple Myeloma Previously Treated with Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib, and Daratumumab and Refractory to Pri | $379,577 | 0 | 67 |
| Phase Ib trial of Low-Dose Selinexor (KPT-330) in combination with Choline Salicylate (CS) for the treatment of patients with residual/relapsed/refractory non-Hodgkin lymphoma (NHL) | $340,788 | 0 | 14 |
| KCP-330-023 | $336,950 | 0 | 134 |
| Evaluating the impact of novel inhibitors of nuclear pore export in SLE | $321,028 | 0 | 5 |
| A Phase 3 Randomized Controlled, Open-Label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM) | $286,225 | 2 | 118 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Hakan Kaya, M.d, M.D | Medical Oncology | Spokane, WA | $516,436 | $0 |
| Mohammadbagher Ziari, Md, MD | Hematology & Oncology | Corona, CA | $275,557 | $0 |
| Kelly Mccaul, M.d, M.D | Hematology & Oncology | Sioux Falls, SD | $229,465 | $0 |
| Ehsan Malek, M.d, M.D | Medical Oncology | Buffalo, NY | $189,256 | $0 |
| Dr. Moshe Levy, Md, MD | Medical Oncology | Dallas, TX | $170,316 | $0 |
| Dr. James Berenson, M.d, M.D | Specialist | West Hollywood, CA | $167,083 | $0 |
| Dr. Kevin Kelly, M.d, M.D | Hematology & Oncology | Los Angeles, CA | $139,915 | $0 |
| Rajesh Behl, M.d, M.D | Hematology & Oncology | Berkeley, CA | $138,418 | $0 |
| Cristina Gasparetto, M.d, M.D | Hematology & Oncology | Durham, NC | $136,662 | $0 |
| Taral Patel, Md, MD | Medical Oncology | Columbus, OH | $134,316 | $0 |
| Dr. Rahul Naik, M.d, M.D | Internal Medicine | Los Angeles, CA | $125,316 | $0 |
| Dr. Robert Vescio, M.d, M.D | Hematology & Oncology | Los Angeles, CA | $120,763 | $0 |
| Dr. Joseph Mikhael, M.d, M.D | Hematology | Scottsdale, AZ | $120,192 | $0 |
| Dr. Daniel Landau, Md, MD | Hematology & Oncology | Orlando, FL | $101,943 | $0 |
| Mojtaba Akhtari, M.d, M.D | Internal Medicine | Omaha, NE | $93,199 | $0 |
| Dr. Binod Dhakal, Md, MD | Internal Medicine | Milwaukee, WI | $85,718 | $0 |
| Michael Schuster, Md, MD | Internal Medicine | New York, NY | $84,452 | $0 |
| Dr. Bruce Cheson, Md, MD | Hematology & Oncology | Bethesda, MD | $82,920 | $0 |
| Dr. Hardeep Phull, Md, MD | Internal Medicine | Escondido, CA | $82,821 | $0 |
| Hamza Hashmi, M.d, M.D | Internal Medicine | Charleston, SC | $80,574 | $0 |
| Tarek Chidiac, Md, MD | Medical Oncology | Columbus, OH | $76,955 | $0 |
| Dr. Christopher Maisel, Md, MD | Hematology & Oncology | Dallas, TX | $76,002 | $0 |
| Kasra Karamlou, M.d, M.D | Hematology & Oncology | Sandusky, OH | $72,997 | $0 |
| Ralph Boccia, M.d, M.D | Medical Oncology | Bethesda, MD | $71,108 | $0 |
| Yogesh Jethava, Md, MD | Hematology | Park Ridge, IL | $67,347 | $0 |
About Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc. has made $48.6M in payments to 7,608 healthcare providers, recorded across 31,668 transactions in the CMS Open Payments database. In 2024, the company paid $5.6M. The top product by payment volume is XPOVIO ($46.3M).
Payments were distributed across 113 medical specialties. The top specialty by payment amount is Hematology & Oncology ($2.8M to 2,137 doctors).
Payment categories include: Food & Beverage ($602,075), Consulting ($1.1M), Research ($41.4M), Travel & Lodging ($570,945).
Karyopharm Therapeutics Inc. is associated with 1 products in the CMS Open Payments database.